



### PROGRAMME OVERVIEW

update October 19, 2021

**November 25, 2021**

**Venue: CORPUS CONGRESS CENTRE - Oegstgeest  
the Netherlands**

## *'Breaking barriers for our future'*

07:45 **Registration desks open breakfast sessions**

---

08:00 **CxO breakfast meeting:** for CEOs, CFOs, COOs and CBOs active in the life sciences sector

*Limited places are available and only to MT members from (R&D) life sciences companies who are attending the conference.*

08:00 **Investors forum part 1 - breakfast session -**

hosted by   
INNOVATION

**MODERATOR: Dr. Harrold van Barlingen, Managing Partner at Thuja Capital**

*The investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, medtech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to all major Dutch life sciences investors and discuss your business strategy, technology direction and capital-raising plan.*

Pitching companies:

- AND BioPharma BV
- Amber Implants BV
- Digi.bio
- ENPICOM
- GOAL 3
- Keystonemab b.v.
- Panorama Laboratories

---

08:45 **Registration desk, exhibition and innovation square open**

---



09:30-10:45 **Plenary morning programme**

09:30 **Welcome by chair Ida Haisma, Director Leiden Bio Science Park**

09:35 **Opening by Carmen van Vilsteren, Chair Top Sector Life Science & Health**

hosted by



09:45 **Keynote lecture:**

**Novel manufacturing solutions for the rapid and cost-effective development of vaccines by Dr. Menzo Havenga, President & CEO Batavia Biosciences**

There is a constant demand for more affordable vaccines for global health (polio, measles, rubella), as well as new vaccines to protect against emerging virus outbreaks, such as Ebola, Lassa, Marburg, and coronavirus. To keep up with such demand, breakthrough technologies and global collaborations are required that allow flexible, cost-effective and rapid vaccine development. In this presentation, promising novel technologies, flexible manufacturing solutions and views on collaborations within the industry will be presented. These innovations have demonstrated to substantially lower the cost of goods and increase speed of manufacturing. Such innovations are deemed critical to stay ahead of the game and keep millions of people from dying from vaccine preventable diseases.

10:10 **Keynote lecture:**

**Arjen Schippers, Senior Director and Program Head at Europe Cell Therapy Facility, Bristol Myers Squibb Leiden**

10:35 **Venture Challenge**

hosted by 

*The winner of the Venture Challenge Fall 2021 will be announced!*




Presentation by **Dr.ir. Chrétien Herben, Program Director Life Sciences@Work**

10:55 **Break**

Exhibition and innovation square open



11:30-12:45 **Parallel morning sessions**

<p><b>Advance biopharmaceutical manufacturing</b></p> <p>Hosted by</p>  <p>Chair: André van de Sande MSc, MBA</p>	<p>A greater prevalence of large molecule drugs, an increase in the number of personalized medicines, the rise of orphan diseases and the high demand of vaccines is reflects the global pharmaceutical portfolio. This need for high quality and complex medicines is driving innovation in biopharmaceutical manufacturing technologies. Trends and developments are discussed in this session.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Mireille Sanders MSc</b>, Chief Operations Officer at Pharming Group NV</li> <li>▪ <b>Ardena</b>, speaker t.b.a.</li> <li>▪ <b>Dr. Nettie Buitelaar</b>, Chief Business Officer at BiosanaPharma</li> </ul>
<p><b>The Nagoya protocol: its impact on research and development in life sciences</b></p> <p>Hosted by</p>  <p>Chair: Frits Michiels</p>	<p>In this session the critical importance of the growing role of the Nagoya protocol on the access to genetic resources and the fair and equitable sharing of benefits arising from their utilization. What is the impact of the Nagoya protocol on your product development related to the use of pathogens and sequence data? What are the actions to be taken by the companies?</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Dr. Martin Brink</b>, Policy Advisor Centre for Genetic Resources, the Netherlands (CGN), WUR</li> <li>▪ <b>Carolina dos Santos Ribeiro MSc, PhD candidate</b>, Senior Policy Advisor at RIVM - Center for Infectious Disease Control (CIB)</li> </ul>
<p><b>Medical devices to respond to urgent needs</b></p> <p>Hosted by</p>  <p>Chair: Jeroen Verhoeven</p>	<p>Medical devices are playing an important role in diagnosing, monitoring, preventing, and treating of COVID-19. Medical devices companies leverage the latest technological advancements to fulfil unmet needs of patients and health care providers. As medical devices and in-vitro medical devices are strictly regulated, implementing new technologies not only comes with technical challenges, but also with challenges in, e.g., the design and the development and the manufacturing of devices. The two presenters in this session will share their experience in this matter.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Koen Beyers</b>, Founder &amp; Board Member at Voxdale</li> <li>▪ <b>David Nauwelaers</b>, Director of Manufacturing MiDiagnostics</li> </ul>

12:45-14:00 **Lunch, networking** > exhibition and innovation square open



12:45

**Investors forum part 2 - lunch session –**



hosted by **Johnson & Johnson**

INNOVATION

Pitching companies:

- AND BioPharma BV
- Amber Implants BV
- Digi.bio
- GOAL 3
- Keystonemab b.v.
- Panorama Laboratories

**14:00-15:15 Parallel afternoon sessions**

<p><b>Advanced cell- and gene based therapeutics</b></p> <p>Hosted by</p>  <p>Chair: Dr. Frank van Engelenburg</p>	<p>Which next generation cell- and gene based therapeutics are being developed and tested in the clinic. What are the market developments and how will the industry meet the high demand of gene therapy products?</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>uniQure</b>, speaker t.b.a.</li> <li>▪ <b>Marc Kamp</b>, Executive Director Quality at Neogene Therapeutics</li> <li>▪ T.b.a.</li> </ul>
<p><b>Human Microbiome: novel therapeutic strategies and market developments</b></p> <p>Hosted by</p>  <p>Chair: Erik Boonen</p>	<p>Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. Pharma and biotech across many different therapeutic indications and modalities are bringing novel microbiome-based therapies and diagnostics to the clinical domain. This session will include some of the most impactful and promising areas of the microbiome field.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Dries Budding</b>, CEO inBiome</li> <li>▪ <b>Dr. Jonathan de Jonge</b>, COO ARTPred</li> <li>▪ <b>Marco van Es</b>, Co founder Bac2nature</li> </ul>
<p><b>Breakthrough technologies in life sciences</b></p> <p>Hosted by: t.b.a.</p> <p>Chair:</p>	<p>What are technologies that will help the life sciences sector and generate impact for patients. Along with substantial investments in drug discovery, research and development, life sciences companies are also transforming in the new technological areas. In this session these breakthrough technologies will be discussed.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Frederico Muffatto</b>, CEO Digi.Bio</li> <li>▪ T.b.a.</li> <li>▪ T.b.a.</li> </ul>



15:15 **Break, networking** > exhibition and innovation square open

---

16:00 **Announcement winner Investors Forum**

---

16:15 **Closing keynote lecture:**  
**The positive side-effects of the COVID-19 pandemic by**  
**Hans Schikan, PharmD, Special Envoy Vaccines Dutch Ministry of Health, Welfare and Sport**

The ongoing COVID-19 pandemic is devastating, for individual people, societies at large and economies alike. At the same time, due to this 'external enemy' the world has seen unprecedented collaboration, speedy review of innovations and risk sharing between the public and private sector. Which of these 'positive side-effects' of the pandemic should we try to foster and keep, also in the post-pandemic era? What are the lessons learnt?

---

17:00 **Wrap up conference**

17:15 **Reception** > exhibition and innovation square open

18:30 **End of the Dutch Life Sciences 2021 conference**

*Note: the organisation keeps the right to make changes to the programme at any time.*